文献速递白血病

贝林妥欧单抗治疗儿童复发/难治性急性淋巴细胞白血病的I/II期研究

Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
PubMed 文献 · J Clin Oncol · 2016-10-31

这项开放标签I/II期研究评估贝林妥欧单抗在复发/难治性B细胞前体急性淋巴细胞白血病(BCP-ALL)儿童中的安全性、药代动力学、推荐剂量和疗效。I期49例、II期44例,最大耐受剂量为15 µg/m2/d,推荐剂量为前7天5 µg/m2/d后续以15 µg/m2/d;接受推荐剂量的70例中27例(39%;95%CI 27%–51%)在前两周期内达完全缓解,其中14例(52%)达完全微小残留病缓解。

要点

  • 最大耐受剂量为15 µg/m2/d,推荐剂量为前7天5 µg/m2/d后15 µg/m2/d。
  • 接受推荐剂量的70例中,27例(39%;95%CI 27%–51%)前两周期内达完全缓解。
  • 27例完全缓解者中14例(52%)达完全微小残留病缓解。

核心结论

  • 该试验为儿科首个此类试验,显示单药贝林妥欧单抗在复发/难治性BCP-ALL儿童中具有抗白血病活性并获完全微小残留病缓解。
  • 贝林妥欧单抗可能成为该情形下重要的新治疗选择,需在治愈性适应症中进一步研究。

研究设计与样本

  • 开放标签I/II期研究,纳入<18岁复发/难治性BCP-ALL儿童,采用6周治疗周期。
  • I期49例、II期44例;I期主要终点为最大耐受剂量,II期主要终点为前两周期内完全缓解率。

主要发现

  • I期第1周期4例出现剂量限制性毒性;3例发生4级细胞因子释放综合征(其中1例归因于5级心脏衰竭),1例发生致死性呼吸衰竭。
  • 贝林妥欧单抗药代动力学在各剂量水平呈线性,各年龄组间一致。
  • 接受推荐剂量的70例中,27例(39%;95%CI 27%–51%)前两周期内达完全缓解,其中14例(52%)达完全微小残留病缓解。
  • 最常见≥3级不良事件为贫血(36%)、血小板减少(21%)和低钾血症(17%);3级和4级细胞因子释放综合征分别见于3例(4%)和1例(1%);2例(3%)因2级癫痫发作中断治疗。

关键数值与推荐

  • 最大耐受剂量为15 µg/m2/d。
  • 基于I期数据,复发/难治性ALL儿童的推荐贝林妥欧单抗剂量为前7天5 µg/m2/d,之后15 µg/m2/d。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需在治愈性适应症中进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on B-cell lymphoblasts. We evaluated the safety, pharmacokinetics, recommended dosage, and potential for efficacy of blinatumomab in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Methods This open-label study enrolled children < 18 years old with relapsed/refractory BCP-ALL in a phase I dosage-escalation part and a phase II part, using 6-week treatment cycles. Primary end points were maximum-tolerated dosage (phase I) and complete remission rate within the first two cycles (phase II). Results We treated 49 patients in phase I and 44 patients in phase II. Four patients had dose-limiting toxicities in cycle 1 (phase I). Three experienced grade 4 cytokine-release syndrome (one attributed to grade 5 cardiac failure); one had fatal respiratory failure. The maximum-tolerated dosage was 15 µg/m2/d. Blinatumomab pharmacokinetics was linear across dosage levels and consistent among age groups. On the basis of the phase I data, the recommended blinatumomab dosage for children with relapsed/refractory ALL was 5 µg/m2/d for the first 7 days, followed by 15 µg/m2/d thereafter. Among the 70 patients who received the recommended dosage, 27 (39%; 95% CI, 27% to 51%) achieved complete remission within the first two cycles, 14 (52%) of whom achieved complete minimal residual disease response. The most frequent grade ≥ 3 adverse events were anemia (36%), thrombocytopenia (21%), and hypokalemia (17%). Three patients (4%) and one patient (1%) had cytokine-release syndrome of grade 3 and 4, respectively. Two patients (3%) interrupted treatment after grade 2 seizures. Conclusion This trial, which to the best of our knowledge was the first such trial in pediatrics, demonstrated antileukemic activity of single-agent blinatumomab with complete minimal residual disease response in children with relapsed/refractory BCP-ALL. Blinatumomab may represent an important new treatment option in this setting, requiring further investigation in curative indications.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. J Clin Oncol. 2016. PMID: 27998223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。